Yuichiro� Doki

51.2k total citations · 9 hit papers
1.4k papers, 34.8k citations indexed

About

Yuichiro� Doki is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yuichiro� Doki has authored 1.4k papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 719 papers in Surgery, 548 papers in Pulmonary and Respiratory Medicine and 518 papers in Oncology. Recurrent topics in Yuichiro� Doki's work include Gastric Cancer Management and Outcomes (346 papers), Esophageal Cancer Research and Treatment (262 papers) and Esophageal and GI Pathology (176 papers). Yuichiro� Doki is often cited by papers focused on Gastric Cancer Management and Outcomes (346 papers), Esophageal Cancer Research and Treatment (262 papers) and Esophageal and GI Pathology (176 papers). Yuichiro� Doki collaborates with scholars based in Japan, United States and Denmark. Yuichiro� Doki's co-authors include Masaki Mori, Shuji Takiguchi, Makoto Yamasaki, Hidetoshi Eguchi, Yukinori Kurokawa, Hiroshi Miyata, Kiyokazu Nakajima, Hideshi Ishii, Hirofumi Yamamoto and Hiroaki Nagano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Yuichiro� Doki

1.3k papers receiving 34.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Yuichiro� Doki et al. profile →
Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs

2011 574 citations Norikatsu Miyoshi, Hideshi Ishii et al. profile →
CD13 is a therapeutic target in human liver cancer stem cells

2010 501 citations Naotsugu Haraguchi, Hideshi Ishii et al. profile →
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

2018 400 citations Yuichiro� Doki et al. profile →
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

2018 367 citations Yuichiro� Doki et al. profile →
Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society

2014 348 citations Yuichiro� Doki et al. profile →
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 292 citations Yuichiro� Doki et al. profile →
Thoracic and cardiovascular surgery in Japan during 2014

2016 267 citations Yuichiro� Doki et al. profile →
Japanese Classification of Esophageal Cancer, 12th Edition: Part I

2024 47 citations Koji Tanaka, Yuichiro� Doki et al. profile →

Peers

Countries citing papers authored by Yuichiro� Doki

Since Specialization

Citations

This map shows the geographic impact of Yuichiro� Doki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichiro� Doki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichiro� Doki more than expected).

Fields of papers citing papers by Yuichiro� Doki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichiro� Doki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichiro� Doki. The network helps show where Yuichiro� Doki may publish in the future.

Co-authorship network of co-authors of Yuichiro� Doki

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichiro� Doki. A scholar is included among the top collaborators of Yuichiro� Doki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichiro� Doki. Yuichiro� Doki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma 2024 ·Cancer Letters ·(unknown), Daisaku Yamada, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Yoshito Tomimaru, (unknown), Takehiro Noda, Hidenori Takahashi, Junzo Shimizu, Yuichiro� Doki, Hidetoshi Eguchi	3
2	Drug Discovery and Development of miRNA-Based Nucleotide Drugs for Gastrointestinal Cancer 2023 ·Biomedicines ·Hiromichi Sato, Tomoaki Hara, (unknown), (unknown), (unknown), Kazuki Sasaki, Norikatsu Miyoshi, Shogo Kobayashi, Yuichiro� Doki, Hidetoshi Eguchi, Hideshi Ishii	0
3	Clinical Significance of Intramural Metastasis as an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma 2023 ·Annals of Surgical Oncology ·Yuki Ushimaru, Tomoki Makino, Koji Tanaka, Kotaro Yamashita, Takuro Saito, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Eiichi Morii, Hidetoshi Eguchi, Yuichiro� Doki	0
4	Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer 2023 ·Annals of Gastroenterological Surgery ·Yoshitomo Yanagimoto, Yukinori Kurokawa, Yuichiro� Doki	20
5	Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids 2021 ·Molecular Cancer Research ·Shiki Fujino, Norikatsu Miyoshi, Aya Ito, Masayoshi Yasui, Masayuki Ohue, Takayuki Ogino, Hidekazu Takahashi, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Yuichiro� Doki, Hidetoshi Eguchi	9
6	Disruption of Endolysosomal RAB5/7 Efficiently Eliminates Colorectal Cancer Stem Cells 2019 ·Cancer Research ·(unknown), Jun Koseki, Hidekazu Takahashi, Norikatsu Miyoshi, Naohiro Nishida, Junichi Nishimura, Taishi Hata, Chu Matsuda, Tsunekazu Mizushima, Hirofumi Yamamoto, Hideshi Ishii, Yuichiro� Doki, Masaki Mori, Naotsugu Haraguchi	51
7	Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment 2018 ·Molecular Cancer Therapeutics ·(unknown), Tsunekazu Mizushima, Xin Wu, Akira Inoue, (unknown), Yuhki Yokoyama, Norikatsu Miyoshi, Naotsugu Haraguchi, Hidekazu Takahashi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Yuichiro� Doki, Masaki Mori, Hirofumi Yamamoto	35
8	p63-Dependent Dickkopf3 Expression Promotes Esophageal Cancer Cell Proliferation via CKAP4 2018 ·Cancer Research ·(unknown), Katsumi Fumoto, Hirokazu Kimura, Satoshi Nojima, (unknown), (unknown), Makoto Yamasaki, Hayato Hikita, Tetsuo Takehara, Yuichiro� Doki, Eiichi Morii, Akira Kikuchi	39
9	A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS -Mutant Colon Cancer Cells 2018 ·Molecular Cancer Therapeutics ·Akira Inoue, Tsunekazu Mizushima, Xin Wu, Daisuke Okuzaki, (unknown), Sho Ishikawa, Jiaqi Wang, (unknown), Haruka Hirose, Yuhki Yokoyama, (unknown), Masayuki Hiraki, Norikatsu Miyoshi, Hidekazu Takahashi, Naotsugu Haraguchi, Taishi Hata, Chu Matsuda, Yuichiro� Doki, Masaki Mori, Hirofumi Yamamoto	30
10	SOCS1 Gene Therapy Improves Radiosensitivity and Enhances Irradiation-Induced DNA Damage in Esophageal Squamous Cell Carcinoma 2017 ·Cancer Research ·Takahito Sugase, Tsuyoshi Takahashi, Satoshi Serada, Minoru Fujimoto, Kosuke Hiramatsu, Tomoharu Ohkawara, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Tadamitsu Kishimoto, Masaki Mori, Yuichiro� Doki, Tetsuji Naka	37
11	Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial 2016 ·Clinical Cancer Research ·Hirofumi Yamamoto, Kohei Murata, Mutsumi Fukunaga, Tadashi Ohnishi, Shingo Noura, Yasuhiro Miyake, Takeshi Kato, Masahisa Ohtsuka, Yurika Nakamura, Ichiro Takemasa, Tsunekazu Mizushima, Masataka Ikeda, Masayuki Ohue, Mitsugu Sekimoto, Riichiro Nezu, Nariaki Matsuura∥, Morito Monden, Yuichiro� Doki, Masaki Mori	32
12	Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer 2015 ·Molecular Cancer Therapeutics ·Hidekazu Takahashi, Junichi Nishimura, Yoshinori Kagawa, Yoshihiro Kano, Yusuke Takahashi, Xin Wu, Masayuki Hiraki, Atsushi Hamabe, Masamitsu Konno, Naotsugu Haraguchi, Ichiro Takemasa, Tsunekazu Mizushima, Masaru Ishii, Koshi Mimori, Hideshi Ishii, Yuichiro� Doki, Masaki Mori, Hirofumi Yamamoto	61
13	Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer 2014 ·Molecular Cancer Therapeutics ·Hiroshi Takeyama, Hirofumi Yamamoto, Shinya Yamashita, Xin Wu, Hidekazu Takahashi, Junichi Nishimura, Naotsugu Haraguchi, Yasuhiro Miyake, Rei Suzuki, Kohei Murata, Masayuki Ohue, Takeshi Kato, Ichiro Takemasa, Tsunekazu Mizushima, Hideshi Ishii, Koshi Mimori, Yuichiro� Doki, Masaki Mori	64
14	Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma 2012 ·Clinical Cancer Research ·Keijiro Sugimura, Hiroshi Miyata, Koji Tanaka, Rie Hamano, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro� Doki	139
15	Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters 2012 ·Clinical Cancer Research ·Naohiro Nishida, Makoto Nagahara, Tetsuya Sato, Koshi Mimori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Kenichi Sugihara, Yuichiro� Doki, Masaki Mori	141
16	MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab 2011 ·Clinical Cancer Research ·Naohiro Nishida, Koshi Mimori, Muller Fabbri, Takehiko Yokobori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Yuichiro� Doki, Masaki Mori	215
17	Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway 2011 ·Clinical Cancer Research ·Rie Hamano, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Johji Hara, Jeong Ho Moon, Kiyokazu Nakajima, Shuji Takiguchi, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro� Doki	216
18	Increased Immunogenicity of Tumor-Associated Antigen, Mucin 1, Engineered to Express α-Gal Epitopes: A Novel Approach to Immunotherapy in Pancreatic Cancer 2010 ·Cancer Research ·Takashi Deguchi, Masahiro Tanemura, Eiji Miyoshi, Hiroaki Nagano, (unknown), Yoshiaki Ohmura, Shogo Kobayashi, Shigeru Marubashi, Hidetoshi Eguchi, Yutaka Takeda, Toshinori Ito, Masaki Mori, Yuichiro� Doki, Yoshiki Sawa	50
19	Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells 2010 ·Clinical Cancer Research ·Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takemasa, Koshi Mimori, (unknown), Tsunekazu Mizushima, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura∥, Yuichiro� Doki, Masaki Mori	80
20	Differential Transcriptome Patterns for Acute Cellular Rejection in Recipients with Recurrent Hepatitis C After Liver Transplantation 2009 ·Liver Transplantation ·Tadafumi Asaoka, Tomoaki Kato, Shigeru Marubashi, Keizo Dono, Naoki Hama, Hidenori Takahashi, Shogo Kobayashi, Yutaka Takeda, Ichiro Takemasa, Hiroaki Nagano, Hideo Yoshida, Phillip Ruiz, Andreas G. Tzakis, Kenichi Matsubara, Morito Monden, Yuichiro� Doki, Masaki Mori	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact